Attention deficit hyperactivity disorder (ADHD) is a common, highly heritable, neurodevelopmental disorder with onset in early childhood. Genes involved in neuronal development and growth are, thus, important etiological candidates and brain-derived neurotrophic factor (BDNF), has been hypothesized to play a role in the pathogenesis of ADHD. BDNF is a member of the neurotrophin family and is involved in the survival and differentiation of dopaminergic neurons in the developing brain (of relevance because drugs that block the dopamine transporter can be effective therapeutically). The common Val66Met functional polymorphism in the human BDNF gene (rs 6265) was genotyped in a collaborative family-based sample of 341 white UK or Irish ADHD probands and their parents. We found evidence for preferential transmission of the valine (G) allele of BDNF (odds ratio, OR ¼ 1.6, P ¼ 0.02) with a strong paternal effect (paternal transmissions: OR ¼ 3.2, P ¼ 0.0005; maternal transmissions: OR ¼ 1.00; P ¼ 1.00). Our findings support the hypothesis that BDNF is involved in the pathogenesis of ADHD. The transmission difference between parents raises the possibility that an epigenetic process may be involved. Molecular Psychiatry (2005) 10, 939-943.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 2-5% of school-aged children with more boys diagnosed than girls. 1 It is characterized by marked and pervasive inattention, overactivity and impulsiveness and causes significant social, educational and psychological problems. Quantitative genetic research over the last decade, from family, twin and adoption studies has firmly established that ADHD has a significant genetic contribution. 2 The medications most often used for ADHD are psychostimulants including methylphenidate and dexamphetamine. Precise therapeutic mechanisms of these drugs in ADHD remain unclear, although methylphenidate is known to inhibit the dopamine transporter. As a result, most candidate gene studies to date have focused on the dopamine system. 3 Positive findings have been successfully replicated for variants in the D4 dopamine receptor (DRD4), 4 D5 dopamine receptor (DRD5) 5 and the dopamine transporter (DAT1). 6 These family-based meta-analyses each report small effect sizes with odds ratios of less than 1.5, indicating that if they are true susceptibility variants for ADHD their contribution to the overall phenotype is small. Given that ADHD is a neurodevelopmental disorder, genes involved in neuronal development and growth represent an important set of candidates for involvement in the pathogenesis. One such candidate that has been postulated to play a role in ADHD is BDNF (MIM 113505). 7 The gene encoding BDNF is located at 11p13 and codes for a precursor peptide (proBDNF), which is proteolytically cleaved to form the mature protein. Only one nonsynonymous polymorphism in the human BDNF gene (rs 6265) has been identified, a single nucleotide polymorphism (SNP) at nucleotide 196 (G/A) that produces an amino-acid substitution (valine to methionine) at codon 66. (We will, henceforth, refer to this as the Val66Met polymorphism.) This is also the only known common variant with potential effect on function. 8 Brief evidence in support of the candidacy of BDNF in ADHD includes the following:
(1) BDNF is a member of the neurotrophin family and is involved in neurodevelopmental processes including the survival and differentiation of dopaminergic neurons in the developing brain 9 as well as being involved in glutamate-dependent neuronal plasticity in the adult. (2) Recent evidence from animal studies demonstrated an increase in BDNF expression in rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration, 10 suggesting that BDNF may have a role in psychostimulant response. (3) Reduced central serotonergic activity has been implicated in poor impulse regulation (a key feature of ADHD) in young children, adults and animals; 11, 12 heterozygous bdnf7mice demonstrate physiologic disturbances in central serotonergic neurons linked with behavioural abnormalities (including increased aggressiveness) suggesting that endogenous BDNF may be critical for the normal development and function of central serotonergic neurons 13 and, hence, impulse regulation. (4) A recent study found evidence that, variation at this same Val66Met polymorphism of BDNF is associated with variation in cognition, 8 providing evidence that BDNF can influence higher brain function that may be relevant to some dimension of ADHD, rather than the categorical diagnosis per se. (5) Finally, the recent family-based studies demonstrating association of the valine allele at the Val66Met polymorphism and bipolar disorder [14] [15] [16] suggest that the val/met polymorphism may be involved in influencing psychopathology. Thus, the Val66Met polymorphism at BDNF has previously been associated with phenotypic changes at the level of disorder and cognition. We have, therefore, examined this polymorphism in the current study of ADHD. We hypothesized that the common valine allele would show preferential transmission to ADHD probands.
Methods
For this study 341 ADHD probands and their parents were recruited from several child psychiatry clinics in the UK and Ireland, following approval from the appropriate research ethics committees. After complete description of the study to the subjects, written informed consent was obtained. Parents were interviewed by trained psychiatrists or psychologists employing the Child and Adolescent Psychiatric Assessment (CAPA). 17 Consistent interview procedures were employed across the three centres with researchers from each centre receiving a common training in the use of the CAPA. In addition, teacher ratings were obtained for 216 (63%) children by teacher telephone interview 18 and the remaining 125 (37%) by the Conners Teacher Rating Scale (CTRS). 19 This was to confirm that symptoms met the criterion of pervasiveness. Established cut-off points for possible and likely ADHD caseness on the CTRS were adhered to that is, a T score above 55 was required. All 341 probands were white and born in the UK or Ireland (mean age ¼ 11.1 years; range 5-16 years; SD 2.8 years). The sample was predominantly male (91%) with no significant difference in sex ratio between the three study recruitment centres. The large male preponderance is likely due to ascertainment bias and reflects the sex ratio seen in the ADHD clinics from where probands were recruited. All probands fulfilled DSM-IV diagnostic criteria for ADHD. Of these, 276 (81%) had ADHD combined type, 31 (9%) had the inattentive subtype and 34 (10%) had the hyperactive impulsive subtype. Children with an IQ below 70, autistic spectrum disorder or significant medical conditions such as epilepsy were excluded. A total of 133 children (39%) had comorbid oppositional defiant disorder and 51 children (15%) fulfilled criteria for comorbid conduct disorder. No children fulfilled diagnostic criteria for major affective disorder (including paediatric onset mania). The criteria for paediatric bipolar disorder/ mania used in the UK are substantially different from those which are employed in the US, such as those of Craney and Geller 20 and in the UK, the two disorders are very distinct. Therefore, from our perspective misdiagnosis is unlikely. Frequencies of subtype and comorbidity were similar across the three recruitment centres.
High molecular weight genomic DNA was extracted from either whole blood or cheek swab according to routine procedures. The Val66Met (dsSNP rs 6265) polymorphism was genotyped by E Green in N Craddock's lab using a fluorescence polarizationbased primer extension assay, 21 using the AcycloPrime Kit (Perkin Elmer) according to the manufacturer's instructions and an analyst genotyping platform (LJL Biosystems). The following ampifluor primers were employed: allele-specific primer 1-5 0 GAAGGTGACCAAGTTCATGCTCATCCAACAGCTC TTCTATCAC; allele-specific primer 2-5 0 GAAGGTC GGAGTCAACGGATTTCCTCATCCAACAGCTCTTCT ATCAT and reverse primer-5 0 GGCTTGACATCAT TGGCTGACA. In order to verify genotyping accuracy, a subset of 100 samples was independently assayed (using either an alternative primer extension method or RFLP). All genotypes were concordant. All genotyping was performed blind to family status and in the case of the duplicates for genotyping accuracy, blind to original genotyping results.
The Transmission Disequilibrium Test (TDT) 22 was used to test for the presence of nonrandom transmission of alleles to ADHD probands at the Val66Met polymorphism indicative of allelic association. Given previous findings of preferential paternal transmission bias with other candidate genes in ADHD, [23] [24] [25] [26] TDTPHASE 27 was used to test transmissions from fathers and mothers separately. The proportions of transmitted vs nontransmitted alleles between ADHD subtypes and comorbid groups were compared using w 2 tests.
Results
Parental and proband allele frequencies are shown in Table 1 . Genotypes demonstrated no significant departure from Hardy-Weinberg equilibrium (for mothers, fathers, parents as a whole and probands). Allele and genotype frequencies did not differ according to recruitment centre. The TDT results for the whole sample and separate parental transmissions are shown in Table 2 . Consistent with our hypothesis there was significant overtransmission of the Val allele (odds ratio (OR) ¼ 1.61, P ¼ 0.02). This was entirely attributable to an excess of paternal transmissions, which was evident in the sample sets from each of the three recruitment centres. Thus, maternal transmissions alone demonstrated no bias (OR ¼ 1, P ¼ 1.00) but there was highly significant overtransmission of the Val allele from fathers (OR ¼ 3.2, P ¼ 0.0005). The parental difference in transmission pattern was statistically significant (P ¼ 0.01). There was no evidence that preferential transmission varied according to subtype of ADHD or whether there was comorbid ODD/CD. (data available on request).
Discussion
These findings are of interest for several reasons. First, we have provided evidence that a neurodevelopmentally relevant gene may be involved in the pathogenesis of ADHD, a finding that, if replicated will broaden the scope of neurobiological research in ADHD from its relatively narrow recent focus on neurotransmitter systems. Second, the finding in our data of a substantial difference in allele transmission between fathers and mothers is intriguing and may inform our understanding of ADHD. Chance is a possible, but unlikely, explanation given the high level of statistical significance, even allowing for multiple testing (P ¼ 0.003 after correction for six tests).
Alternative explanations for the difference between paternal and maternal transmissions include:
(a) Transmission distortion at the BDNF locusGeneralized distortion of the predicted Mendelian transmission of alleles, independent of phenotype, may occur at a locus as a result of biological processes such as gametic selection. However, such an effect has not been previously observed in BDNF and our own previous investigation of BDNF in our bipolar parent-proband trios does not support this possibility. 14 In addition, the presence of Hardy-Weinberg equilibrium in our sample makes this explanation unlikely. (b) Imprinting at BDNF-Imprinting describes the situation in which the expression of an allele is dependent on the parent from which the allele was inherited (in contrast with the usual Mendelian situation in which the parent of origin of an allele is irrelevant). Imprinting is known to occur at loci on chromosome 11p, including the Wilms tumour locus at 11p13. 28 However, imprinting seems an unlikely explanation for the present findings because, despite substantial study, Val66-Met has not been reported previously to show parent of origin effects and we find no evidence of such effect in our own previous bipolar disorder parent-proband trio sample data (published in Sklar et al 14 ) , which would be expected if a common mechanism at BDNF influenced psychopathology in bipolar disorder and ADHD. Further, and more persuasively, we have previously found that in the brain frontal cortex of 16 anonymous white Val/Met heterozygotes, BDNF mRNA from each parental chromosome was expressed at approximately equal levels (data not shown). The samples and methods used are described in detail elsewhere. 29 These findings do not provide information about the functionality (or otherwise) of the Val66Met polymorphism; they demonstrate lack of differential expression of alleles according to parent of origin (ie imprinting) in adult brain frontal cortex. However, developmentally-specific or neuroanatomically tissue-specific imprinting remains a possibility.
To determine the robustness and generalizability of any finding in psychiatric genetics replication in independent data sets is crucial. We are aware of two other studies that have examined the possible role of BDNF in ADHD. In a study that has only been reported in abstract form to date, Lanktree et al 30 describe evidence for the involvement of the valine allele of Val66Met in both a case control and trio analysis of adults with ADHD. This is clearly consistent with our own findings. The second study failed to find any association between Val66Met and childhood ADHD using a small sample (N ¼ 88), but this study's power to detect an association with an effect size of 1.6, at an alpha of 0.05 was only 45%. 31 It is also important to consider that different diagnostic practices between the UK, other parts of Europe and the US may be an issue with regards to the failure to replicate findings, particularly in terms of the differing frequencies of ADHD subtypes and comorbidity seen in other samples.
As mentioned above, the motivation for us undertaking analyses according to parental transmission was the prior observation that paternal preferential transmission bias has been reported in some other studies of candidate genes in ADHD, for example, variants of the synaptosomal associated protein of 25 kDa gene (SNAP 25) 23,24 and the serotonin receptor gene, 5HT1B 25,26. This raises the possibility that the pathogenesis of ADHD could involve some general epigenetic mechanism (such as abnormal imprinting-which could be developmentally-or neuroanatomically-specific) that affects multiple genes. However, the parent of origin effect observed at BDNF in our data requires confirmation in independent samples and, if replicated, the cause(s) will need to be explored further. We note that preferential paternal transmission is unlikely to account on its own for the excess of males with an ADHD diagnosis, given that the preferential transmission occurs regardless of the gender of the proband.
Although the Val66Met is located in the 5 0 pro-BDNF sequence and not the mature BDNF protein, it is the only common variant yet described with a plausible functional effect-it may affect intracellular processing and secretion of BDNF that has been hypothesized to lead to the impairment of neuronal function. 8 It was for this reason that we chose to undertake a specific study of this polymorphism-in order to take advantage of the higher prior probability of pathogenic relevance of a functional variant, test a focused hypothesis and minimize problems of reduced power caused by correction for testing multiple polymorphisms and haplotypes. Our approach represents the most powerful test of the involvement of the only known functional variant in BDNF rather than a (less powerful) test of variation throughout the gene. Thus, if our findings are robust, it is likely that the Val66Met variant itself plays a role in influencing susceptibility-although it remains possible that the findings reflect linkage disequilibrium between the Val66Met polymorphism and variation elsewhere within BDNF or a nearby locus.
In summary, we have demonstrated highly significant overtransmission of a paternal allele of a functionally relevant polymorphism within the BDNF gene to offspring with ADHD. Our findings support the hypothesis that BDNF is involved in the pathogenesis of ADHD. The transmission difference between parents may reflect an epigenetic process.
